文献速递肿瘤 PET/CT

新型68Ga标记D肽拮抗剂用于癌症TIGIT表达PET显像的临床前及探索性人体研究

Preclinical and exploratory human studies of novel 68Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-01-17

本研究开发了68Ga标记的D肽拮抗剂68Ga-GP12,并在体外、体内及非小细胞肺癌患者中验证其用于TIGIT表达PET显像的可行性。68Ga-GP12对TIGIT具有高亲和力(KD=37.28 nM),在荷瘤小鼠中60分钟时肿瘤摄取为4.22±0.68 %ID/g,肿瘤/肌肉比为12.94±2.64。在非小细胞肺癌患者中,68Ga-GP12 PET所显示的原发灶和转移灶与18F-FDG PET所见相当,且病灶摄取和瘤内分布不均匀,提示TIGIT表达存在异质性。

要点

  • 68Ga-GP12对TIGIT具有高亲和力,KD为37.28 nM。
  • 荷瘤小鼠60分钟时肿瘤摄取为4.22±0.68 %ID/g,肿瘤/肌肉比为12.94±2.64。
  • 非小细胞肺癌患者中68Ga-GP12 PET所示原发灶和转移灶与18F-FDG PET所见相当,病灶摄取不均匀提示TIGIT表达异质性。

核心结论

  • 68Ga-GP12是一种有前景的放射性示踪剂,可用于癌症TIGIT表达的PET显像,提示其有潜力作为抗TIGIT治疗的伴随诊断。

研究设计与样本

  • 研究开发了68Ga标记的D肽拮抗剂68Ga-GP12,并在体外、体内及探索性人体研究中验证其用于TIGIT表达PET显像。
  • 体外结合实验在人外周血单核细胞(PBMC)中评估亲和力与特异性,并研究了显像能力、生物分布、药代动力学和辐射剂量学。
  • 采用流式细胞术、放射自显影和免疫组化染色确认TIGIT表达,并在非小细胞肺癌患者中评估68Ga-GP12 PET/CT显像的安全性和潜力。

主要发现

  • 68Ga标记的D肽可方便地制备,具有高放射化学产率、放射化学纯度和摩尔活度。
  • 体外结合实验显示68Ga-GP12对TIGIT具有高亲和力和特异性,KD为37.28 nM。
  • 体内和离体研究显示68Ga-GP12可用于TIGIT表达PET显像,注射后60分钟肿瘤摄取为4.22±0.68 %ID/g,肿瘤/肌肉比为12.94±2.64。
  • 在非小细胞肺癌患者中,68Ga-GP12 PET图像所见原发灶和转移灶与18F-FDG PET图像所见相当。
  • 原发灶和转移灶的示踪剂摄取及大肿瘤内瘤内分布不均匀,提示TIGIT表达存在异质性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: While TIGIT has been propelled as a next-generation target in cancer immunotherapy, anti-TIGIT therapy seems to be promising for a fraction of patients in clinical trials. Therefore, patient stratification is critical for this therapy, which could benefit from a whole-body, non-invasive, and quantitative evaluation of TIGIT expression in cancers. In this study, a 68Ga-labeled D-peptide antagonist, 68Ga-GP12, was developed and validated for PET imaging of TIGIT expression in vitro, in vivo, and in an exploratory human study. METHODS: The D-enantiomer peptide antagonists were modified and radiolabeled with 68Ga. In vitro binding assays were performed in human peripheral blood mononuclear cells (PBMCs) to assess their affinity and specificity. The imaging capacity, biodistribution, pharmacokinetics, and radiation dosimetry were investigated. Flow cytometry, autoradiography, and immunohistochemical staining were used to confirm the expression of TIGIT. The safety and potential of 68Ga-GP12 for PET/CT imaging of TIGIT expression were evaluated in NSCLC patients. RESULTS: 68Ga-labeled D-peptides were conveniently produced with high radiochemical yields, radiochemical purities and molar activities. In vitro binding assays demonstrated 68Ga-GP12 has high affinity and specificity for TIGIT with a KD of 37.28 nM. In vivo and ex vivo studies demonstrated the capacity of 68Ga-GP12 for PET imaging of TIGIT expression with high tumor uptake of 4.22 ± 0.68 %ID/g and the tumor-to-muscle ratio of 12.94 ± 2.64 at 60 min post-injection. In NSCLC patients, primary and metastatic lesions found in 68Ga-GP12 PET images were comparable to that in 18F-FDG PET images. Moreover, tracer uptake in primary and metastatic lesions and intra-tumoral distribution in the large tumor were inhomogenous, indicating the heterogeneity of TIGIT expression. CONCLUSION: 68Ga-GP12 is a promising radiotracer for PET imaging of TIGIT expression in cancers, indicating its potential as a potential companion diagnostic for anti-TIGIT therapies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wang X, Zhou M, Chen B, et al. Preclinical and exploratory human studies of novel 68Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers. Eur J Nucl Med Mol Imaging. 2022. PMID: 35037984. doi:10.1007/s00259-021-05672-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。